Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Based on the early promising data for injectable cagrilintide semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP 1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace What Novo Nordisk's disappointing trial results mean for the obesity drug market Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination